Cargando…
Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumours
CITED1 is a non-DNA binding transcriptional co-regulator whose expression can distinguish the ‘proliferative’ from ‘invasive’ signature in the phenotype-switching model of melanoma. We have found that, in addition to other ‘proliferative’ signature genes, CITED1 expression is repressed by TGFβ while...
Autores principales: | Howlin, Jillian, Cirenajwis, Helena, Lettiero, Barbara, Staaf, Johan, Lauss, Martin, Saal, Lao, Borg, Åke, Gruvberger-Saal, Sofia, Jönsson, Göran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4349148/ https://www.ncbi.nlm.nih.gov/pubmed/25755924 http://dx.doi.org/10.7717/peerj.788 |
Ejemplares similares
-
CITED1 as a marker of favourable outcome in anti-endocrine treated, estrogen-receptor positive, lymph-node negative breast cancer
por: Dahlgren, Malin, et al.
Publicado: (2023) -
Molecular and genetic diversity in the metastatic process of melanoma
por: Harbst, Katja, et al.
Publicado: (2014) -
Molecular stratification of metastatic melanoma using gene expression profiling : Prediction of survival outcome and benefit from molecular targeted therapy
por: Cirenajwis, Helena, et al.
Publicado: (2015) -
NF1‐mutated melanoma tumors harbor distinct clinical and biological characteristics
por: Cirenajwis, Helena, et al.
Publicado: (2017) -
BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data
por: Saal, Lao H, et al.
Publicado: (2002)